e-learning
resources
ERS Research Seminars
2019
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
What are the main mechanisms of oncogenic addiction?
Joanna Chorostowska (Poland)
Source:
New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine
Number:
1
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Joanna Chorostowska (Poland). What are the main mechanisms of oncogenic addiction?. New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Is there a place for ICI in the context of oncogenic addiction?
Source: ERS Research Seminar 2017 – Immunotherapy: a new standard of care in thoracic malignancies?
Year: 2017
Asthma phenotypes: do metabolic pathways hold the key?
Source: International Congress 2017 – Metabolism in respiratory diseases: time for a rethink
Year: 2017
Understanding nicotine addiction and the principles of harm reduction
Source: International Congress 2018 – Emerging tobacco products and harm reduction: a tobacco solution to a tobacco problem?
Year: 2018
Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies?
Source: Eur Respir J, 59 (2) 2102417; 10.1183/13993003.02417-2021
Year: 2022
Long COVID: to investigate immunological mechanisms and sex/gender related aspects as fundamental steps for tailored therapy
Source: Eur Respir J, 59 (2) 2102245; 10.1183/13993003.02245-2021
Year: 2022
Nicotine addiction in animals : mechanisms and models
Source: Research Seminar 2005 - Tobacco Smoking: Harm Reduction Strategies
Year: 2005
Mechanisms underlying nicotine dependency
Source: International Congress 2014 – End of the tobacco epidemic: from individual to societal strategies
Year: 2014
COPD mechanisms: novel aspects and implications for new therapies
Source: ERS Live 2007
Year: 2007
Therapeutic strategy for other oncogenic drivers
Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine
Year: 2019
Breaking news: DNA damage and repair pathways in COPD and implications for pathogenesis and treatment
Source: Eur Respir J, 52 (4) 1801718; 10.1183/13993003.01718-2018
Year: 2018
Dysregulation of host defence peptides by environmental challenge: Can we mitigate the pathophysiology?
Source: International Congress 2019 – Infections, the microbiome and host defence peptides in the development and progression of asthma
Year: 2019
What are the targets?
Source: Respiratory Failure and Mechanical Ventilation Conference 2020
Year: 2020
Bringing it all together: common pathways, emerging therapeutics and future directions
Source: International Congress 2014 – From bench to bronchiole: translational immunology and airways disease
Year: 2014
Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities
Source: Eur Respir J 2014; 44: 513-522
Year: 2014
Understanding nicotine addiction and the health effects of nicotine use
Source: Eur Respir Monogr 2021; 90: 18-32
Year: 2021
Pathogenetic mechanisms common to disease progression in fibrotic ILDs: the yang of pathogenetic thinking
Source: International Congress 2019 – Lumping and splitting of fibrotic interstitial lung diseases
Year: 2019
Narcolepsy: evolving understanding of the mechanisms
Source: Annual Congress 2003 - The brain and the lung: interactions
Year: 2003
Targeting intermittent hypoxia downstream pathways for biomarker discovery and new treatment perspectives in cutaneous melanoma
Source: Eur Respir J, 53 (2) 1802444; 10.1183/13993003.02444-2018
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept